Articles by tag: weight-loss

Survodutide trials: failure or effectiveness in weight loss?

Phase 3 SYNCHRONIZE-1 analysis: weight loss 13-16.6%, but 19% discontinuations due to side effects. Is it worth the risk? Read the full review.

EMA recommended the first oral GLP-1 drug for weight loss | Wegovy

EMA issued a positive opinion on the first oral GLP-1 Wegovy for weight loss. Analysis of efficacy, price, side effects and market forecast. Read details.

EMA approved the first oral GLP-1 drug Wegovy for weight control

EMA recommended the first GLP-1 tablet for weight loss — Wegovy (semaglutide) 25 mg. Efficacy up to 16.6% weight loss. Market analysis, winners and losers. Learn more.

Oral GLP-1 tablet for weight loss: EMA analysis

EMA decision analysis on oral semaglutide (Wegovy Pill). OASIS 4 data, investments in Ireland and competition with Lilly. Read forecasts and hidden risks.

Fibermaxing: a natural alternative to Ozempic in 2026

Fibermaxing — the 2026 trend: how fiber is replacing GLP-1 injections and changing the market. Find out who is making money and who is threatened by the new dietary standard.

Budget Express Diets 2026: The Hidden Meaning of the Trend

Analysis of the Cheap Diet Trend: Why the Apple-Kefir Diet for 1747 RUB Is a Trap. Find out who profits from your weight loss and what the real cost is. Read the analysis.

63% of Russians want to lose weight by summer 2026: survey and trends

Almost two-thirds of Russians plan to lose weight by beach season. How weight loss methods are divided into sports and diets, and why the healthy food market grew by 27% — in the study.